SAVE Moms and Babies Act of 2023 Support And Value Expectant Moms and Babies Act of 2023
If enacted, SB95 would enforce that no new applications for abortion drugs can be approved, effectively halting any future developments in this area. Additionally, previously approved abortion drugs would face numerous new regulations including in-person administration by certified health care practitioners only, required risk evaluations and mitigation strategies, and mandatory reporting of any adverse events associated with their use. This could lead to reduced availability and increased difficulties for expectant mothers seeking abortions through medical means, significantly impacting state laws regarding reproductive health.
SB95, known as the 'Support And Value Expectant Moms and Babies Act of 2023' or the 'SAVE Moms and Babies Act of 2023', seeks to amend the Federal Food, Drug, and Cosmetic Act significantly. The primary objective of the bill is to prohibit the approval of new abortion drugs and investigational use exemptions for existing abortion drugs. Furthermore, it imposes stricter regulations on previously approved abortion drugs, creating an entirely new framework for how abortion-related medications are managed within the healthcare system.
Moreover, the bill's requirement that healthcare practitioners have specific qualifications and the ability to perform surgical interventions raises questions about the practicality of implementation and the potential burden it places on medical facilities. This aspect could lead to disparities in access to reproductive health services, particularly in rural or underserved areas.